Management Team
Board of Directors
Scientific Advisory Board
 |
ANAVEX Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer, inflammatory and neurological diseases (CNS). The company's diverse development program is dynamically driven by its highly skilled scientific team of biochemists, molecular pharmacologists, and biologists, in collaboration with leading academic institutions. ANAVEX pipeline portfolio is continually enriched by new compounds with unique mode of action and blockbuster potential. Most of our drug candidates have demonstrated high affinity for a fairly new class of receptors (sigma-1 and sigma-2) involved in the modulation of multiple cellular biochemical signaling pathways. Eleven new sigma ligands in late pre-clinical stage target the two therapeutic areas described below. These product candidates are expected to enter clinical trials within 2008.
Neurological diseases (CNS): Alzheimer's disease, epilepsy and depression, where ANAVEX lead candidates exhibit strong evidence of anti-amnesic, neuro-protective, anti-apoptotic, anti-oxidative, anti-convulsive, anti-depressant, anti-fatigue, and anti-addictive properties.
Oncology: Our sigma receptor ligands induced apoptosis during in-vitro and in-vivo studies in various types of cancers such as, colon, prostate, breast, and lung, demonstrating evidence of pro-apoptotic and anti-metastatic action with low toxicity
In addition, several series of sigma ligands currently at different stages of development, target cancer, acute ischemic stroke, multiple sclerosis and Parkinson's disease.
